Identification of candidate metabolite biomarkers for metabolic syndrome and its five components in population-based human cohorts
Authors' conclusion
Our identified candidate metabolite biomarkers are associated with the pathophysiology of MetS and its risk factors. They could facilitate the development of therapeutic strategies to prevent type 2 diabetes and cardiovascular disease. For instance, elevated levels of lysoPC a C18:2 may protect MetS and its five risk components. More in-depth studies are necessary to determine the mechanism of key metabolites in the MetS pathophysiology.
Study context
- Population
- Participants of the KORA F4 study (discovery) and the SHIP-TREND-0 study (replication); serum, 121 metabolitesKORA F4 N = 2815
- Exposure
- Individuals with Metabolic Syndrome (MetS) vs controls
- Outcome
- Metabolites Bonferroni significantly associated with MetS
Methodological detailsdiscovery and replication cohorts, multiple regression adjusted for clinical and lifestyle covariates, Bonferroni significance
- Discovery and replication cohorts
- Multiple regression adjusted for clinical and lifestyle covariates
- Bonferroni significance
Main finding
As reported in the abstract
MetS-specific metabolites identified and replicated
56
Positively associated (e.g., Val, Leu/Ile, Phe, Tyr)
13
Negatively associated (e.g., Gly, Ser, 40 lipids)
43
Observational data: associations, not effects.
Further findings
Association of MetS-specific metabolites with MetS components
- Associated with low high-density lipoprotein cholesterol (HDL-C)
- 89%
- Associated with hypertension
- 23%
- lysoPC a C18:2 negatively associated with MetS and all five components (lower concentrations vs controls)
Metabolic networks
- Impaired catabolism of branched-chain and aromatic amino acids, and accelerated Gly catabolism
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →